Tago reported that the 2-arylhydroxyquinoline derivative [11C]-THK951 demonstrated excellent kinetics in a normal mouse brain (3.23% ID/g at 2 min post-injection and 0.15% ID/g at 30 min post-injection) and showed the labeling of NFTs in an AD brain section by autoradiography assay, indicating the availability of [11C]-THK951 for in vivo PET imaging of tau pathology in AD [14,15]. This evidence concerns the gene MAPT and Alzheimer disease.